Depósito Digital de Documentos de la UAB Encontrados 3 registros  La búsqueda tardó 0.01 segundos. 
1.
10 p, 2.7 MB A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer / Yamamoto, Nobuyuki (Wakayama Medical University. Third Department of Internal Medicine) ; Hayashi, Hidetoshi (Kindai University Faculty of Medicine. Department of Medical Oncology) ; Planchard, David (Institut Gustave Roussy. Department of Medical Oncology, Thoracic Group) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gregorc, Vanesa (IRCCS Ospedale San Raffaele. Department of Oncology, Division of Experimental Medicine) ; Dowell, Jonathan (University of Texas Southwestern Medical Center. Department of Internal Medicine) ; Sakai, Hiroshi (Saitama Cancer Center. Department of Thoracic Oncology) ; Yoh, Kiyotaka (National Cancer Center Hospital East. Department of Thoracic Oncology) ; Nishio, Makoto (The Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Department of Thoracic Medical Oncology) ; Cortot, Alexis B. (Centre Hospitalier Universitaire de Lille. Thoracic Oncology Department) ; Benhadji, Karim A. (Taiho Oncology, Inc. Department of Clinical Development) ; Soni, Nital (Taiho Oncology, Inc. Department of Clinical Development) ; Huang, Jinhong (Taiho Pharmaceutical Co., Ltd. Department of Pharmacovigilance) ; Makris, Lukas (Stathmi, Inc, 125 Brownsburg Rd, New Hope, PA 18938 USA) ; Cedres, Susana (VHIO) ; Universitat Autònoma de Barcelona
The online version of this article (10. 1007/s10637-020-00930-5) contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00930-5
Investigational New Drugs, Vol. 38 (april 2020) , p. 1588-1597  
2.
10 p, 595.1 KB Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma / Wick, Antje (Heidelberg University Medical Center. Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center) ; Desjardins, Annick (Duke University. The Preston Robert Tisch Brain Tumor Center at Duke) ; Suarez, Cristina (VHIO) ; Forsyth, Peter (H. Lee Moffitt Cancer Center and Research Institute) ; Gueorguieva, Ivelina (Eli Lilly and Company) ; Burkholder, Tiana (Eli Lilly and Company) ; Cleverly, Ann Louise (Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company) ; Wang, Shuaicheng (BioStat Solutions, Inc, Frederick, MD USA) ; Lahn, Michael M. (Eli Lilly and Company) ; Guba, Susan C. (Eli Lilly and Company) ; Capper, David (Department of Neuropathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany) ; Rodon Ahnert, Jordi (VHIO) ; Universitat Autònoma de Barcelona
The online version of this article (10. 1007/s10637-020-00910-9) contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00910-9
Investigational New Drugs, Vol. 38 (march 2020) , p. 1570-1579  
3.
14 p, 1.9 MB Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer / Rodón, Jordi (Hospital Universitari Vall d'Hebron) ; Carducci, Michael (Johns Hopkins Kimmel Cancer Center) ; Sepulveda-Sánchez, Juan M. (Hospital Universitario 12 de Octubre) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Calvo, Emiliano (START Madrid, Centro Integral Oncológico Clara Campal) ; Seoane, Joan (Hospital Universitari Vall d'Hebron) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Gueorguieva, Ivelina (Eli Lilly and Company) ; Cleverly, Ann (Eli Lilly and Company) ; Pillay, N. Sokalingum (Eli Lilly and Company) ; Desaiah, Durisala (Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company) ; Paz-Ares, Luis (Hospital Virgen del Rocío, Sevilla, Spain) ; Holdhoff, Matthias (Johns Hopkins Kimmel Cancer Center) ; Blakeley, Jaishri (Johns Hopkins University) ; Lahn, Michael M. (Eli Lilly and Company) ; Baselga, Jose (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Purpose Transforming growth factor-beta (TGF-β) signaling plays a key role in epithelial-mesenchymal transition (EMT) of tumors, including malignant glioma. Small molecule inhibitors (SMI) blocking TGF-β signaling reverse EMT and arrest tumor progression. [...]
2014 - 10.1007/s10637-014-0192-4
Investigational New Drugs, Vol. 33 (december 2014) , p. 357-370  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.